FDA approves Angiotech's Hemo-Stream

Angiotech has added one more brick to its stable of end stage renal disease treatment products. The company today got FDA clearance to sell a chronic dialysis catheter it licensed from Rex Medical in April. Known as Hemo-Stream, the catheter is designed to increase flow rates and cut the risk of complications such as embolism and bleeding.

Angiotech previously acquired a related vascular graft business, and it's enrolling for European trials of its Vascular Wrap AV product, a drug-coated device designed to keep permanent dialysis access points open.

- read the release for more info

Related Articles:
Angiotech buys Quill Medical. Report
CombinatoRx gains $7M from extended Angiotech pact. Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.